Immunology Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract - Immunology Case Reports (2021) Volume 4, Issue 4

The therapeutic P140 peptide, a new immunomodulating tool for lupus may have applications in other chronic inflammatory conditions

P140 is a synthetic peptide issued from the U1-70K protein. It was chemically modified and contains a phosphoserine residue at position 140. P140/Lupuzorâ had no adverse safety signals and met its primary efficacy end points in a multicenter, randomized, placebo-controlled phase IIb study for lupus. A phase III-clinical trial is currently on-going for this indication. The mechanism of action of P140 has been recently elucidated in MRL/lpr lupus-prone mice. P140 binds HSPA8/ HSC70 chaperone protein, decreases its expression and reduces autophagic flux in B-lymphocytes of peptide-treated MRL/ lpr mice. P140 interferes with a selective form of autophagy called chaperone-mediated autophagy or CMA. It induces a lower expression class II-MHC molecules and alters the presentation of peptides to autoreactive T cells, leading to a reduction T and B cells activation and a drop of potentially pathogenic autoantibodies. 

Author(s): Sylviane Muller

Abstract Full Text PDF

Get the App